ADXS Key Statistics, Chart & Performance
The current stock price of ADXS is 0.155 null. In the past month the price decreased by -61.41%. In the past year, price decreased by -59.74%.
ADXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About ADXS
Company Profile
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Company Info
ADVAXIS INC
9 Deer Park Drive, Suite K-1
Monmouth Junction NEW JERSEY 08540 US
CEO: Kenneth Berlin
Employees: 18
Phone: 17325451590.0
ADVAXIS INC / ADXS FAQ
What does ADXS do?
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Can you provide the latest stock price for ADVAXIS INC?
The current stock price of ADXS is 0.155 null. The price decreased by -35.42% in the last trading session.
What is the dividend status of ADVAXIS INC?
ADXS does not pay a dividend.
What is the ChartMill rating of ADVAXIS INC stock?
ADXS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ADXS stock listed?
ADXS stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for ADXS stock?
ADVAXIS INC (ADXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
ADXS Technical Analysis
ADXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADXS. ADXS has a bad profitability rating. Also its financial health evaluation is rather negative.
ADXS Financial Highlights
Over the last trailing twelve months ADXS reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 58.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -581.85% | ||
| ROA | -37.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ADXS Forecast & Estimates
7 analysts have analysed ADXS and the average price target is 2.3 null. This implies a price increase of 1380.65% is expected in the next year compared to the current price of 0.155.